Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema versus insulin glargine plus insulin aspart in adults with inadequately controlled type 2 diabetes on basal insulin
2020-005309-18Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of icosema, insulin glargine and insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Aug 2021; status: completed.
02
Drugs
icosemainsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-005309-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005309-18.